Clinical trial · Observational
Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)
Treatment Patterns Among Patients With Advanced Small Cell Lung Cancer (SCLC) in Europe
NCT03425825CI-TRIAL-00056173completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-interventional, retrospective study of advanced SCLC patients in 4 European countries (France, Germany, Italy, and United Kingdom \[UK\]) with the aim to produce evidence across different SCLC treatment lines to characterize the clinical and economic burden of the disease in Europe.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- LD-SCLC receiving 1st line treatment
- description
- patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
- label
- ED-SCLC receiving 1st line treatment
- description
- patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
- label
- relapsed/refractory receiving 2nd or later-line treatment
- description
- relapsed/refractory patients receiving second- or later-line treatment
Primary outcomes (7)
- measure
- Distribution of Patient Demographic Characteristics
- timeFrame
- At baseline
- description
- Characteristics include: Age/month and year of birth Gender Ethnicity Weight Height Smoking status Alcohol consumption Other relevant risk factors
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Cohort 1 and 2: * Patients 18 years of age or older at SCLC diagnosis * Confirmed diagnosis of SCLC within the patient identification period (between October 2013 and October 2015) * Initiated on first-line treatment (radiotherapy and/or chemotherapy) for their SCLC * Full oncology medical history for the mandatory variables of the study available in the participating center from day of diagnosis until the end of follow-up or death (whichever occurs first) * Signed informed consent (where required as per local requirements) Cohort 3: * Patients 18 years of age or older at SCLC diagnosis * Confirmed diagnosis of SCLC not earlier than October 2013 * Initiated on second-line treatment due to relapse after first-line therapy not later than August 2016 * Full oncology medical history for the mandatory variables of the study available in the participating center from day of diagnosis until the end of follow-up or death (whichever occurs first) * Signed informed consent (where required as per local requirements) Exclusion Criteria: * Participants with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to first treatment and no additional therapy is required or anticipated to be required during the study period. Other Inclusion/Exclusion criteria may apply
References
Publications (0)
Data not yet available
No reference posted for this study.